CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) of -$13.50 million for the 12-month period ending 2025-12-27, per its 10-K filed 2026-02-18.
Financial Statements › Notes › Compensation Related Costs › Retirement Benefits › Defined Benefit Plan › Defined Benefit Plan, Roll Forwards
us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation · last filed 2026-02-18
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, benefit obligation, foreign currency translation gain (loss) for fiscal 2025 was -$13.50M, a 502.11% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, benefit obligation, foreign currency translation gain (loss) for fiscal 2024 was $3.36M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, benefit obligation, foreign currency translation gain (loss) for fiscal 2023 was -$8.44M, a 140.99% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. defined benefit plan, benefit obligation, foreign currency translation gain (loss) for fiscal 2022 was $20.59M, a 787.25% increase from fiscal 2021.
| Period end | Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss) 12 month |
|---|---|
| 2025-12-27 | -$13.50M 10-K · filed 2026-02-18 |
| 2024-12-28 | $3.36M 10-K · filed 2026-02-18 |
| 2023-12-30 | -$8.44M 10-K · filed 2025-02-19 |
| 2022-12-31 | $20.59M 10-K · filed 2024-02-14 |
| 2021-12-25 | $2.32M 10-K · filed 2023-02-22 |
| 2020-12-26 | -$9.06M 10-K · filed 2022-02-16 |
| 2019-12-28 | -$7.53M 10-K · filed 2021-02-17 |
| 2018-12-29 | $14.97M 10-K · filed 2020-02-11 |
| 2017-12-30 | -$24.36M 10-K · filed 2019-02-13 |
| 2016-12-31 | $36.48M 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |